Overview
ASMB market data
Price History
ASMB price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.55 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.11 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $15.84 – $39.71 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $462.5 · P/B 2.60 · P/S 6.51.
Company news
Assembli to Produce Big Ten Conference Activation at Fanatics Fest in New YorkGlobenewswire Inc · Jul 16, 2026, 6:31 PM
Mizuho Maintains Outperform on Assembly Biosciences, Raises Price Target to $45Benzinga · Jun 15, 2026, 5:25 PM
8-K filing — ASSEMBLY BIOSCIENCES, INC. (ASMB)SEC EDGAR · Jun 5, 2026, 8:00 PM
Guggenheim Reiterates Buy on Assembly Biosciences, Maintains $43 Price TargetBenzinga · May 28, 2026, 1:35 PM
Crude Oil Edges Higher; US Consumer Sentiment Falls In MayBenzinga · May 22, 2026, 5:05 PM
Zoom Upbeat Q1 Results, Joins Lionsgate Studios, Ross Stores And Other Big Stocks Moving Higher On FridayBenzinga · May 22, 2026, 2:05 PM
Assembly Biosciences Prices $100M Offering Of 3,358,602 At $26.50 Per Share And Warrants To Purchase Up To 415,000 Shares At Offer Price Of $26.499 Per Pre-Funded WarrantBenzinga · May 22, 2026, 11:15 AM
Assembly Biosciences Announces Plans To Expand Clinical Development Of ABI-6250 Into Primary Biliary Cholangitis And Primary Sclerosing CholangitisBenzinga · May 22, 2026, 11:10 AM
Assembly Biosciences To Present First-In-Class Oral Hepatitis D Virus Entry Inhibitor ABI-6250 Data At EASL Congress 2026Benzinga · May 13, 2026, 6:43 AM
Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care ConferenceGlobenewswire Inc · May 11, 2026, 12:05 PM